The Indian company Ranbaxy will resume production of its generic version of the anti-cholesterol drug Lipitor in the United States, according to a Reuters story.
The company had recalled the drug, called atorvastatin, in November after particles of glass were found in certain lots.
The original Lipitor, manufactured by Pfizer Inc., has also been the source of some safety concerns.
The U.S. Food and Drug Administration has added warnings to the labels of ...
continue reading...
A study linked the cholesterol drug Tredaptive to serious side effects that included development of diabetes, gastrointestinal problems, bleeding and infections, according to a Reuters report.
Manufacturer Merck had already decided not to sell the drug in the United States and to take it off the market in dozens of other countries, after findings that it failed to prevent heart attacks, strokes, death and other complications in heart patients.
Tredaptive isn’t ...
continue reading...
A Massachusetts drug compounder called Pallimed Solutions has voluntarily recalled more than a dozen sterile drugs and compounds following an inspection, CNN reports.
Although the company says it has no indication that any if its products are unsafe or contaminated, it did not reveal what the inspection found that prompted the recall.
Compounding pharmacies prepare specialty variations on prescriptions for individual patients in response to physician orders. They aren’t subject to ...
continue reading...
A Georgia compounding pharmacy called Clinical Specialties is recalling syringes of the drug Avastin, following reports that they may have caused eye infections.
Compounding pharmacies prepare specialty drugs from components provided by other sources, in response to individual orders from physicians. CBS News reports that Avastin is approved as a cancer drug. But compounding pharmacies such as Clinical Specialties have been repackaging it into small vials so eye doctors can ...
continue reading...
A blog post on Forbes deals with Johnson & Johnson’s type 2 diabetes drug Canagliflozin, which is expected to receive FDA approval soon and which the report describes as having “blockbuster potential.”
According to the report, Canagliflozin proved effective at lowering blood glucose levels and causing weight loss in diabetics during clinical trials. But it also showed potentially troubling side effects, in the form of elevated risk for heart problems.
The item ...
continue reading...
The plaintiff in the second trial over the DePuy Orthopaedics ASR hip implant is seeking punitive damages – indicating “fraud or malice” – as well as compensatory damages, according to Reuters.
The first trial of nearly 11,000 such cases recently concluded in Los Angeles. Although the jury in that case rejected punitive damages, Johnson & Johnson’s DePuy Orthopaedics division must still pay the defendant – a retired prison guard who said ...
continue reading...
